-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationTom Lee
Since Biogen's Alzheimer's drug Aduhelm (aducanumab) was approved by the U.
On November 10, the company said it was investigating the death of a 75-year-old woman who died of ARIA while receiving Aduhelm
Clinicians expressed concern about the safety risks of the drug's ongoing outbreaks, saying that the subjects in Aduhelm's initial clinical trial were generally healthy except for early Alzheimer's disease, with other comorbidities were often excluded from the Aduhelm trial to remove interference from confounding factors
On Monday (November 22), JAMA Neurology published a study by Biogen, Brown University, University College London, VU University Medical Center Amsterdam, The Netherlands, California Pacific Medical Center, San Francisco, Bioclinica, Newark, California, and Walther, Massachusetts.
The researchers found ARIA in 425 patients (41.
Biogen Aduhelm was controversial at the time of approval and before
Contrasted with Aduhelm's uncertain efficacy and risk of side effects, the drug is priced at around $56,000 per patient per year, and many U.
Aduhelm has so far failed to make satisfactory progress on the market, with Biogen reporting just $300,000 in sales for the drug in the third quarter
Reference source: Study: Biogen's Aduhelm Caused Brain Swelling in Over One-Third of Study Participants
